Phase I trial of carboplatin and infusional cyclosporine in advanced malignancy

Robert J. Morgan, Kim Margolin, James Raschko, Steven Akman, Lucille Leong, George Somlo, Kevin Scanlon, Chul Ahn, Mary Carroll, James H. Doroshow

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Purpose: To determine the maximal-tolerated dose (MTD) of infusional cyclosporine (CSA) with fixed-dose carboplatin (CBDCA). Patients and Methods: Clonogenic cytotoxicity assays were performed to assess the effect of CSA on reversal of resistance to CBDCA. The phase I study was performed in three phases. In phases 1 and 2, escalating-dose CSA (5, 7.5, 8.8, or 9.5 mg/kg/d) with fixed-dose CBDCA 300 or 250 mg/m2 were administered. Phase 3 required an initial cycle of CBDCA 250 mg/m2 alone, followed by combination therapy with CBDCA 250 mg/m2 and CSA (8.8, 9.5, or 10.0 mg/kg/d). Results: Preincubation of platinum-resistant A2780 human ovarian cancer cells with CSA 2 μg/mL significantly enhanced CBDCA cytotoxicity in clonogenic assays. Fifty-one patients received 130 courses of therapy. The phase 1 MTD was thrombocytopenia (CSA 7.5 mg/kg/d and CBDCA 300 mg/m2) attributable to the effects of CBDCA alone. The phase 2 MTD was reversible nephrotoxicity (serum creatinine elevations to 3.6 and 4.4 mg/dL) and neutropenia (CSA 9.5 mg/kg/d and CBDCA 250 mg/m2). In phase 3, headache was observed in five patients and hypertension in one patient at CSA 10 mg/kg/d. The expected change in platelet count predicted for CBDCA alone was compared with the actual change; no excessive thrombocytopenia was observed with addition of CSA. Steady- state CSA levels of 2 μg/mL capable of reversing platinum resistance in vitro were observed. Four objective responses were observed. Conclusion: CSA is effective in reversing CBDCA resistance in A2780 ovarian cancer cells. Short-term infusions of CSA ≤ 8.8 mg/kg/d in combination with CBDCA are well-tolerated for heavily pretreated patients and result in CSA levels known to reverse CBDCA resistance in vitro.

Original languageEnglish (US)
Pages (from-to)2238-2246
Number of pages9
JournalJournal of Clinical Oncology
Volume13
Issue number9
StatePublished - Sep 1995

Fingerprint

Carboplatin
Cyclosporine
Neoplasms
Maximum Tolerated Dose
Platinum
Thrombocytopenia
Ovarian Neoplasms
Neutropenia
Platelet Count
Headache
Creatinine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Morgan, R. J., Margolin, K., Raschko, J., Akman, S., Leong, L., Somlo, G., ... Doroshow, J. H. (1995). Phase I trial of carboplatin and infusional cyclosporine in advanced malignancy. Journal of Clinical Oncology, 13(9), 2238-2246.

Phase I trial of carboplatin and infusional cyclosporine in advanced malignancy. / Morgan, Robert J.; Margolin, Kim; Raschko, James; Akman, Steven; Leong, Lucille; Somlo, George; Scanlon, Kevin; Ahn, Chul; Carroll, Mary; Doroshow, James H.

In: Journal of Clinical Oncology, Vol. 13, No. 9, 09.1995, p. 2238-2246.

Research output: Contribution to journalArticle

Morgan, RJ, Margolin, K, Raschko, J, Akman, S, Leong, L, Somlo, G, Scanlon, K, Ahn, C, Carroll, M & Doroshow, JH 1995, 'Phase I trial of carboplatin and infusional cyclosporine in advanced malignancy', Journal of Clinical Oncology, vol. 13, no. 9, pp. 2238-2246.
Morgan RJ, Margolin K, Raschko J, Akman S, Leong L, Somlo G et al. Phase I trial of carboplatin and infusional cyclosporine in advanced malignancy. Journal of Clinical Oncology. 1995 Sep;13(9):2238-2246.
Morgan, Robert J. ; Margolin, Kim ; Raschko, James ; Akman, Steven ; Leong, Lucille ; Somlo, George ; Scanlon, Kevin ; Ahn, Chul ; Carroll, Mary ; Doroshow, James H. / Phase I trial of carboplatin and infusional cyclosporine in advanced malignancy. In: Journal of Clinical Oncology. 1995 ; Vol. 13, No. 9. pp. 2238-2246.
@article{9a383a5580e04b41b4b0b46baf52b2f6,
title = "Phase I trial of carboplatin and infusional cyclosporine in advanced malignancy",
abstract = "Purpose: To determine the maximal-tolerated dose (MTD) of infusional cyclosporine (CSA) with fixed-dose carboplatin (CBDCA). Patients and Methods: Clonogenic cytotoxicity assays were performed to assess the effect of CSA on reversal of resistance to CBDCA. The phase I study was performed in three phases. In phases 1 and 2, escalating-dose CSA (5, 7.5, 8.8, or 9.5 mg/kg/d) with fixed-dose CBDCA 300 or 250 mg/m2 were administered. Phase 3 required an initial cycle of CBDCA 250 mg/m2 alone, followed by combination therapy with CBDCA 250 mg/m2 and CSA (8.8, 9.5, or 10.0 mg/kg/d). Results: Preincubation of platinum-resistant A2780 human ovarian cancer cells with CSA 2 μg/mL significantly enhanced CBDCA cytotoxicity in clonogenic assays. Fifty-one patients received 130 courses of therapy. The phase 1 MTD was thrombocytopenia (CSA 7.5 mg/kg/d and CBDCA 300 mg/m2) attributable to the effects of CBDCA alone. The phase 2 MTD was reversible nephrotoxicity (serum creatinine elevations to 3.6 and 4.4 mg/dL) and neutropenia (CSA 9.5 mg/kg/d and CBDCA 250 mg/m2). In phase 3, headache was observed in five patients and hypertension in one patient at CSA 10 mg/kg/d. The expected change in platelet count predicted for CBDCA alone was compared with the actual change; no excessive thrombocytopenia was observed with addition of CSA. Steady- state CSA levels of 2 μg/mL capable of reversing platinum resistance in vitro were observed. Four objective responses were observed. Conclusion: CSA is effective in reversing CBDCA resistance in A2780 ovarian cancer cells. Short-term infusions of CSA ≤ 8.8 mg/kg/d in combination with CBDCA are well-tolerated for heavily pretreated patients and result in CSA levels known to reverse CBDCA resistance in vitro.",
author = "Morgan, {Robert J.} and Kim Margolin and James Raschko and Steven Akman and Lucille Leong and George Somlo and Kevin Scanlon and Chul Ahn and Mary Carroll and Doroshow, {James H.}",
year = "1995",
month = "9",
language = "English (US)",
volume = "13",
pages = "2238--2246",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "9",

}

TY - JOUR

T1 - Phase I trial of carboplatin and infusional cyclosporine in advanced malignancy

AU - Morgan, Robert J.

AU - Margolin, Kim

AU - Raschko, James

AU - Akman, Steven

AU - Leong, Lucille

AU - Somlo, George

AU - Scanlon, Kevin

AU - Ahn, Chul

AU - Carroll, Mary

AU - Doroshow, James H.

PY - 1995/9

Y1 - 1995/9

N2 - Purpose: To determine the maximal-tolerated dose (MTD) of infusional cyclosporine (CSA) with fixed-dose carboplatin (CBDCA). Patients and Methods: Clonogenic cytotoxicity assays were performed to assess the effect of CSA on reversal of resistance to CBDCA. The phase I study was performed in three phases. In phases 1 and 2, escalating-dose CSA (5, 7.5, 8.8, or 9.5 mg/kg/d) with fixed-dose CBDCA 300 or 250 mg/m2 were administered. Phase 3 required an initial cycle of CBDCA 250 mg/m2 alone, followed by combination therapy with CBDCA 250 mg/m2 and CSA (8.8, 9.5, or 10.0 mg/kg/d). Results: Preincubation of platinum-resistant A2780 human ovarian cancer cells with CSA 2 μg/mL significantly enhanced CBDCA cytotoxicity in clonogenic assays. Fifty-one patients received 130 courses of therapy. The phase 1 MTD was thrombocytopenia (CSA 7.5 mg/kg/d and CBDCA 300 mg/m2) attributable to the effects of CBDCA alone. The phase 2 MTD was reversible nephrotoxicity (serum creatinine elevations to 3.6 and 4.4 mg/dL) and neutropenia (CSA 9.5 mg/kg/d and CBDCA 250 mg/m2). In phase 3, headache was observed in five patients and hypertension in one patient at CSA 10 mg/kg/d. The expected change in platelet count predicted for CBDCA alone was compared with the actual change; no excessive thrombocytopenia was observed with addition of CSA. Steady- state CSA levels of 2 μg/mL capable of reversing platinum resistance in vitro were observed. Four objective responses were observed. Conclusion: CSA is effective in reversing CBDCA resistance in A2780 ovarian cancer cells. Short-term infusions of CSA ≤ 8.8 mg/kg/d in combination with CBDCA are well-tolerated for heavily pretreated patients and result in CSA levels known to reverse CBDCA resistance in vitro.

AB - Purpose: To determine the maximal-tolerated dose (MTD) of infusional cyclosporine (CSA) with fixed-dose carboplatin (CBDCA). Patients and Methods: Clonogenic cytotoxicity assays were performed to assess the effect of CSA on reversal of resistance to CBDCA. The phase I study was performed in three phases. In phases 1 and 2, escalating-dose CSA (5, 7.5, 8.8, or 9.5 mg/kg/d) with fixed-dose CBDCA 300 or 250 mg/m2 were administered. Phase 3 required an initial cycle of CBDCA 250 mg/m2 alone, followed by combination therapy with CBDCA 250 mg/m2 and CSA (8.8, 9.5, or 10.0 mg/kg/d). Results: Preincubation of platinum-resistant A2780 human ovarian cancer cells with CSA 2 μg/mL significantly enhanced CBDCA cytotoxicity in clonogenic assays. Fifty-one patients received 130 courses of therapy. The phase 1 MTD was thrombocytopenia (CSA 7.5 mg/kg/d and CBDCA 300 mg/m2) attributable to the effects of CBDCA alone. The phase 2 MTD was reversible nephrotoxicity (serum creatinine elevations to 3.6 and 4.4 mg/dL) and neutropenia (CSA 9.5 mg/kg/d and CBDCA 250 mg/m2). In phase 3, headache was observed in five patients and hypertension in one patient at CSA 10 mg/kg/d. The expected change in platelet count predicted for CBDCA alone was compared with the actual change; no excessive thrombocytopenia was observed with addition of CSA. Steady- state CSA levels of 2 μg/mL capable of reversing platinum resistance in vitro were observed. Four objective responses were observed. Conclusion: CSA is effective in reversing CBDCA resistance in A2780 ovarian cancer cells. Short-term infusions of CSA ≤ 8.8 mg/kg/d in combination with CBDCA are well-tolerated for heavily pretreated patients and result in CSA levels known to reverse CBDCA resistance in vitro.

UR - http://www.scopus.com/inward/record.url?scp=0029151578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029151578&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 2238

EP - 2246

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 9

ER -